- The FDA accepts for review AstraZeneca's (NASDAQ:AZN -0.3%) supplemental New Drug Application (sNDA) seeking approval for PARP inhibitor LYNPARZA (olaparib) for the treatment of patients with BRCA mutation-positive, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy, the first potential indication beyond ovarian cancer.
- The FDA's action date will be in Q1 2018.
FDA accepts AstraZeneca's marketing application for expanded use of cancer med Lynparza
Recommended For You
More Trending News
About AZN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AZN | - | - |
AstraZeneca PLC |